Verona Pharma plc (VRNA)
NASDAQ: VRNA · Real-Time Price · USD
67.96
+3.77 (5.87%)
At close: Feb 21, 2025, 4:00 PM
68.25
+0.29 (0.43%)
After-hours: Feb 21, 2025, 4:51 PM EST
Verona Pharma Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Verona Pharma stock have an average target of 57.14, with a low estimate of 33 and a high estimate of 74. The average target predicts a decrease of -15.92% from the current stock price of 67.96.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Verona Pharma stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $44 → $72 | Strong Buy | Maintains | $44 → $72 | +5.94% | Feb 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $42 → $60 | Strong Buy | Reiterates | $42 → $60 | -11.71% | Jan 21, 2025 |
| Roth MKM | Roth MKM | Strong Buy Initiates $68 | Strong Buy | Initiates | $68 | +0.06% | Jan 10, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $64 → $74 | Buy | Maintains | $64 → $74 | +8.89% | Jan 8, 2025 |
| Truist Securities | Truist Securities | Strong Buy Reiterates $44 → $57 | Strong Buy | Reiterates | $44 → $57 | -16.13% | Jan 8, 2025 |
Financial Forecast
Revenue This Year
36.12M
Revenue Next Year
242.51M
from 36.12M
Increased by 571.44%
EPS This Year
-1.70
from -0.72
EPS Next Year
-0.33
from -1.70
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 44.1M | 341.8M | 636.3M | |||
| Avg | 36.1M | 242.5M | 474.1M | |||
| Low | 16.9M | 138.9M | 237.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 846.3% | 162.4% | |||
| Avg | - | 571.4% | 95.5% | |||
| Low | - | 284.5% | -2.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.28 | 0.03 | 1.58 | |||
| Avg | -1.70 | -0.33 | 0.78 | |||
| Low | -2.21 | -0.67 | 0.02 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.